The Service of the Commission for the Protection of Competition has received a notification of a concentration, according to Section 10 of the Control of Concentrations between Enterprises Law of 2014, concerning the acquisition of the sharecapital of Intersect ENT, Inc. by Medtronic, Inc..
Medtronic, Inc. is a company duly registered under the laws of Minneapolis, USA, that is which is a global company of medical equipment and technology and its mission is to contribute to human well-being by applying biomedical engineering to research, design, manufacture and sale of products to relieve pain, restore health and prolong life. Its products deal with about 70 health conditions.
The Target in this concentration is Intersect ENT, Inc., a company duly registered under the laws of California, USA, which is a medical technology company dedicated to promoting the treatment of certain sinus conditions through data-driven innovation, providing physicians with solutions to overcome clinical challenges and improve patients' quality of life. Intersect manufactures bioabsorbable sinus implants used in postoperative sinus surgeries to reduce inflammation through medication.